Nurix (NRIX) Chief Legal Officer exercises options and sells 11,008 shares

Rhea-AI Filing Summary

Nurix Therapeutics, Inc. Chief Legal Officer Christine Ring reported an option exercise-and-sale transaction in company stock. She exercised employee stock options to acquire a total of 11,008 shares of common stock at exercise prices of $8.72 and $1.86 per share, then sold 11,008 shares in an open-market sale at a weighted average price of $23.5616 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan. After these transactions, she directly holds 13,579 shares of common stock and retains an employee stock option covering 128,611 shares at an exercise price of $8.72 per share, expiring on February 12, 2034.

Insider Trade Summary 10b5-1

Net Seller: 11,008 shares ($259,366)

Net Sell 5 txns

Insider Ring Christine

Role Chief Legal Officer

Sold 11,008 shs ($259K)

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	5,221	$0.00	--
Exercise	Employee Stock Option (right to buy)	5,787	$0.00	--
Exercise	Common Stock	5,221	$1.86	$10K
Exercise	Common Stock	5,787	$8.72	$50K
Sale	Common Stock	11,008	$23.5616	$259K

Holdings After Transaction: Employee Stock Option (right to buy) — 0 shares (Direct, null); Common Stock — 18,800 shares (Direct, null)

Footnotes (1)

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. Represents the weighted average sale price. The lowest price at which shares were sold was $23.23 and the highest price at which shares were sold was $24.16. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein. The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Shares sold: 11,008 shares Weighted average sale price: $23.5616 per share Options exercised at $8.72: 5,787 shares +3 more

6 metrics

Shares sold 11,008 shares Open-market sale of common stock

Weighted average sale price $23.5616 per share Common stock sale on 2026-07-02

Options exercised at $8.72 5,787 shares Employee stock option exercise

Options exercised at $1.86 5,221 shares Employee stock option exercise

Shares owned after transactions 13,579 shares Direct common stock holdings post-transaction

Remaining option grant 128,611 options at $8.72 Employee stock option expiring February 12, 2034

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (right to buy), open-market sale, weighted average sale price, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy) ... underlying security title Common Stock"

open-market sale financial

"transaction_action open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average sale price financial

"Represents the weighted average sale price."

exercise or conversion of derivative security financial

"transaction_code_description Exercise or conversion of derivative security"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 06:03 PM Accepted by SEC EDGAR 07/02/2026 - 06:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ring Christine

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1600 SIERRA POINT PKWY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2026		M(1)		5,221	A	$1.86	18,800	D
Common Stock	07/02/2026		M(1)		5,787	A	$8.72	24,587	D
Common Stock	07/02/2026		S(1)		11,008	D	$23.5616(2)	13,579	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.86	07/02/2026		M(1)			5,221	(3)	09/30/2029	Common Stock	5,221	$0	0	D
Employee Stock Option (right to buy)	$8.72	07/02/2026		M(1)			5,787	(4)	02/12/2034	Common Stock	5,787	$0	128,611	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $23.23 and the highest price at which shares were sold was $24.16. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.

4. The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Christine Ring	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Nurix Therapeutics (NRIX) executive Christine Ring report in this Form 4?

Christine Ring, Chief Legal Officer of Nurix Therapeutics, reported exercising employee stock options for 11,008 shares and selling 11,008 common shares in an open-market transaction. The filing also updates her remaining share and option holdings following these transactions.

How many Nurix Therapeutics (NRIX) shares did Christine Ring sell and at what price?

She sold 11,008 shares of Nurix Therapeutics common stock in an open-market sale at a weighted average price of $23.5616 per share. Individual sale prices ranged from $23.23 to $24.16, according to the weighted-average pricing footnote in the filing.

What stock options did Christine Ring exercise in this Nurix Therapeutics (NRIX) filing?

She exercised options covering 5,787 shares at an exercise price of $8.72 per share and 5,221 shares at an exercise price of $1.86 per share. These exercises converted previously granted employee stock options into Nurix Therapeutics common shares.

How many Nurix Therapeutics (NRIX) shares does Christine Ring own after the reported transactions?

Following the reported option exercises and sale, Christine Ring directly owns 13,579 shares of Nurix Therapeutics common stock. This post-transaction figure reflects her updated direct equity position as shown in the Form 4 ownership table.

Does Christine Ring still hold Nurix Therapeutics (NRIX) stock options after this Form 4?

Yes. After exercising part of an option grant, she continues to hold an employee stock option for 128,611 shares at an exercise price of $8.72 per share, with an expiration date of February 12, 2034, subject to its vesting terms.

Were the Nurix Therapeutics (NRIX) share sales by Christine Ring pre-planned?

Yes. The filing states the sale transaction was effected under a previously adopted Rule 10b5-1 trading plan. Such plans are pre-arranged programs that schedule trades in advance, helping separate trading activity from day-to-day market timing decisions.